Related Experiment Video
Updated: Aug 6, 2025

Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of
Yingxiu Luo1,2, Mengjia He1,2, Jie Yang1,2
1Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Abstract:
Retinoblastoma, the most prevalent primary intraocular tumor in children, leads to vision impairment, disability and even death. In addition to RB1 inactivation, MYCN activation has been documented as another common oncogenic alteration in retinoblastoma and represents one of the high-risk molecular subtypes of retinoblastoma. However, how MYCN contributes to the progression of retinoblastoma is still incompletely understood. Here, we report that MYCN upregulates YTHDF1, which encodes one of the reader proteins for N6-methyladenosine (m6A) RNA modification, in retinoblastoma. We further found that this MYCN-upregulated m6A reader functions to promote retinoblastoma cell proliferation and tumor growth in an m6A binding-dependent manner. Mechanistically, YTHDF1 promotes the expression of multiple oncogenes by binding to their mRNAs and enhancing mRNA stability and translation in retinoblastoma cells. Taken together, our findings reveal a novel MYCN-YTHDF1 regulatory cascade in controlling retinoblastoma cell proliferation and tumor growth, pinpointing an unprecedented mechanism for MYCN amplification and/or activation to promote retinoblastoma progression.
Insights
MYCN activation drives retinoblastoma progression by upregulating YTHDF1, an m6A reader protein. This promotes cancer cell growth through enhanced oncogene expression, revealing a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Retinoblastoma is the most common childhood intraocular tumor, with MYCN activation defining a high-risk subtype.
- The precise role of MYCN in retinoblastoma progression remains unclear.
Purpose of the Study:
- To elucidate the mechanism by which MYCN contributes to retinoblastoma pathogenesis.
- To investigate the role of N6-methyladenosine (m6A) RNA modification in MYCN-driven retinoblastoma.
Main Methods:
- Analysis of MYCN and YTHDF1 expression in retinoblastoma.
- Investigation of YTHDF1's function in retinoblastoma cell proliferation and tumor growth.
- Assessment of m6A binding-dependent mechanisms.
Main Results:
- MYCN was found to upregulate YTHDF1, a key reader protein in m6A RNA modification.
- YTHDF1 promotes retinoblastoma cell proliferation and tumor growth in an m6A binding-dependent manner.
- YTHDF1 enhances oncogene expression by increasing mRNA stability and translation.
Conclusions:
- A novel MYCN-YTHDF1 regulatory cascade controls retinoblastoma cell proliferation and tumor growth.
- This pathway offers a new understanding of MYCN's role in retinoblastoma and presents a potential therapeutic target.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
MAPK Signaling Cascades
The Ras Gene
Ras is a...

